@article{stamper_papich_lewbart_may_plummer_stoskopf_2003, title={Pharmacokinetics of florfenicol in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections}, volume={34}, DOI={10.1638/1042-7260(2003)34[0003:pofils]2.0.co;2}, abstractNote={Abstract The pharmocodynamics of single injections of florfenicol in yearling loggerhead sea turtles (Caretta caretta) were determined. Eight juvenile loggerhead sea turtles weighing 1.25 (±0.18) kg were divided into two groups. Four animals received 30 mg/kg of florfenicol i.v., and four received the same dose i.m. Plasma florfenicol concentrations were analyzed by reverse-phase high performance liquid chromatography. After the i.v. dose, there was a biphasic decline in plasma florfenicol concentration. The initial steep phase from 3 min to 1 hr had a half-life of 3 min, and there was a longer slow phase of elimination, with a half-life that ranged from 2 to 7.8 hr among turtles. The volume of distribution varied greatly and ranged from 10.46 to –60 L/kg. Clearance after the i.v. dose was 3.6–6.3 L/kg/hr. After the i.m. injection, there was a peak within 30 min of 1.4–5.6 μg/ml, and florfenicol was thereafter eliminated with a half-life of 3.2–4.3 hr. With either route, florfenicol plasma concentrations were below the minimum inhibitory concentrations for sensitive bacteria within 1 hr. Florfenicol does not appear to be a practical antibiotic in sea turtles when administered at these doses.}, number={1}, journal={Journal of Zoo and Wildlife Medicine}, author={Stamper, M. A. and Papich, Mark and Lewbart, Gregory and May, S. B. and Plummer, D. D. and Stoskopf, M. K.}, year={2003}, pages={3–8} }
 @article{stamper_papich_lewbart_may_plummer_stoskopf_1999, title={Pharmacokinetics of ceftazidime in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular injections}, volume={30}, number={1}, journal={Journal of Zoo and Wildlife Medicine}, author={Stamper, M. A. and Papich, M. G. and Lewbart, G. A. and May, S. B. and Plummer, D. D. and Stoskopf, M. K.}, year={1999}, pages={32–35} }
 @article{lankford_plummer_hellyer_christ_bai_1997, title={Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model}, volume={30}, ISSN={["1533-4023"]}, DOI={10.1097/00005344-199711000-00008}, abstractNote={The pharmacokinetics of losartan and EXP3174, an active metabolite of losartan, were evaluated in the anesthetized pig after both a single intravenous dose (3 mg/kg) and during constant intravenous infusion. The pharmacodynamic activities of losartan and EXP3174 were determined during constant intravenous infusion as the degree of inhibition of angiotensin II-induced increase in the diastolic pressure. The systemic plasma clearance of losartan was 22.1 +/- 4.4 ml/min/kg (mean +/- SEM) and had an apparent volume of distribution at steady state of 0.56 +/- 0.16 L/kg after a 3-mg/kg intravenous dose. The elimination half-life of losartan was 40 +/- 6 min. Less than 2% of the intravenous losartan doses was estimated to be present as unconjugated EXP3174. The plasma clearance of EXP3174 was approximately 50% that of losartan, 11.8 +/- 1.5 ml/min/kg, and had a smaller steady-state apparent volume of distribution, 0.18 +/- 0.04 L/kg. The elimination half-life for EXP3174 was slightly longer than that of losartan (52 min). The time course of the pharmacodynamic effects of losartan and EXP3174 closely followed their respective plasma concentrations. The apparent dissociation constant of EXP3174 to the angiotensin II receptor was estimated, based on the total plasma concentrations, to be approximately 5 times lower than that for losartan.}, number={5}, journal={JOURNAL OF CARDIOVASCULAR PHARMACOLOGY}, author={Lankford, SM and Plummer, D and Hellyer, P and Christ, DD and Bai, SA}, year={1997}, month={Nov}, pages={583–590} }